相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格:
T25
KYSE180/KYSE180细胞系/KYSE180细胞株/KYSE180人食道癌肿瘤细胞
Cell line name KYSE-180
Synonyms KYSE 180; KYSE180; Kyse180; KY180
Accession CVCL_1349
Resource Identification Initiative To cite this cell line use: KYSE-180 (RRID:CVCL_1349)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: 15.2 hours (PubMed=1728357); ~40-50 hours (DSMZ=ACC-379).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
PubMed=7913084; DOI=10.1002/ijc.2910580224
Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H., Fukumoto M.
Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines.
Int. J. Cancer 58:291-297(1994)
PubMed=8575860; DOI=10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.0.CO;2-C
Tanaka H., Shibagaki I., Shimada Y., Wagata T., Imamura M., Ishizaki K.
Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors.
Int. J. Cancer 65:372-376(1996)
PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C
Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.
Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines.
Int. J. Cancer 70:437-442(1997)
PubMed=11092977; DOI=10.1111/j.1349-7006.2000.tb00895.x; PMCID=PMC5926289
Pimkhaokham A., Shimada Y., Fukuda Y., Kurihara N., Imoto I., Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.
Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon.
Jpn. J. Cancer Res. 91:1126-1133(2000)
PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172
Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K., Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.
Cancer Res. 64:3741-3747(2004)
PubMed=16045545; DOI=10.1111/j.0959-9673.2005.00431.x; PMCID=PMC2517430
Ban S., Michikawa Y., Ishikawa K.-i., Sagara M., Watanabe K., Shimada Y., Inazawa J., Imai T.
Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines.
Int. J. Exp. Pathol. 86:231-240(2005)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注:由上海酶研生物科技有限公司提供;
*发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.
【求助】180KD的膜蛋白western转膜条件怎样?(湿转)
zhywang4072 鄙人现在做一180KD的蛋白,之前转PVDF膜用的是100v两个半小时,预染marker转得很漂亮,内参也很不错,但是目标蛋白条带却没有,请教各位大侠,这是什么原因?还有诸位大蛋白转膜时候条件怎样?我用的是湿转,谢谢 wodezxn 我觉得100V2h肯定是足够了,没转上应该是你目的蛋白的问题,可能是蛋白表达量太少或者你提蛋白的时间有问题。 zhibinx2007
:yuweibayuweibaer7号女孩昵称:蛋壳几几年哒:1995专业:心血管城市:南京中医药大学对对方的期待:会动物实验,细胞实验,meta分析,生信分析微信:许愿的香炉8号女孩昵称:媛女SJY几几年哒:1991专业:临床检验诊断学城市:连云港对对方的期待:希望结识乐观上进,身高175cm及以上,92年到88年之间的男孩纸微信:188528671859号女孩昵称:圈三儿~几几年哒:1995专业:药剂学城市:南京对对方的期待:180+,乐观上进微信:amy1518980067333310号女孩昵称:茹夏几几年哒:1992
的 PromoCell DC 生成培养基 DXF(不含细胞因子)洗三次, 吸走 上清液。 3、开始分化为不成熟的单核 DC 细胞(第 0 天) 加入适量的混有 1x 化合物 A 的 P romoCell DC 生成培养基 DXF,在 37 ℃和 5 %的 CO2 的培养箱中培养3天。 4、更换培养基(第 3 天) 在第3天的时候更换 培养基:从细胞中吸走培养基,收集在一个离心管中。然后立刻吸取新鲜的与1x化合物A混合的DC生成培养基DXF加入到细胞中。在 180g 的离心力条件下离心10
技术资料






